2.58

2.64% -0.07

Lantern Pharma Inc (LTRN)

Overview News Price History Option Chain Financials Discussions Forecast

Lantern Pharma Inc stock is traded at $2.58, with a volume of 83,427. It is down -2.64% in the last 24 hours and down -10.10% over the past month. Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Previous Close:

$2.65

Open:

$2.59

24h Volume:

83,427

Relative Volume:

0.42

Market Cap:

$33.11M

Revenue:

Net Income/Loss:

$-15.91M

P/E Ratio:

-1.7855

EPS:

-1.445

Net Cash Flow:

$-15.07M

1W Performance:

-8.19%

1M Performance:

-10.10%

6M Performance:

-5.82%

1Y Performance:

-43.54%

1-Day Range:

$2.485

$2.62

1-Week Range:

$2.35

$2.87

52-Week Range:

$1.11

$4.75

Lantern Pharma Inc Stock (LTRN) Company Profile

Name

Lantern Pharma Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

972-277-1136

Address

1920 MCKINNEY AVENUE, DALLAS, TX

Employee

Twitter

@lanternpharma

Next Earnings Date

2026-08-14

Latest SEC Filings

LTRN's Discussions on Twitter

Compare LTRN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LTRN Lantern Pharma Inc	2.59	33.88M	0	-15.91M	-15.07M	-1.445
VRTX Vertex Pharmaceuticals Inc	515.46	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.15	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.36	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.40	39.31B	5.76B	514.49M	1.10B	4.4813

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-21	Initiated	H.C. Wainwright	Buy

Lantern Pharma Inc Stock (LTRN) Latest News

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc Stock (LTRN) Company Profile

Compare LTRN vs VRTX, REGN, ARGX, RVMD, ONC

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Lantern Pharma Inc Stock (LTRN) Latest News

Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Market Signals Mixed on Growth Prospects - GuruFocus

Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria

LTRN: Static price chart | Lantern Pharma Inc. | US51654W1018 - marketscreener.com

Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet

Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet

Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus

Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada

Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria

LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView

LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView

Lantern Pharma Q2 2026 Earnings Call Transcript - marketbeat.com

BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt

Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade

Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Ea - GuruFocus

Lantern Pharma Forms Open Medicine AI Subsidiary Business - TipRanks

Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price - TradingView

Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary - TradingView

Lantern Pharma Reports $7.1 Million Q2 Net Loss as LP-184 Trial Clears - Quiver Quantitative

Lung cancer trial narrows focus after 8.9-month progression-free result - Stock Titan

Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN - marketbeat.com

Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits

Lantern Pharma Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

Empery Asset Management, LP Acquires 1.3 Million Shares of Lantern Pharma Inc (LTRN) - GuruFocus

LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire

LTRN Price History for Lantern Pharma Stock - Barchart.com

LTRN Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Lantern Pharma (LTRN): Empery Asset Management discloses 9.99% beneficial stake - Stock Titan

Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Lantern Pharma Spins Off Open-Medicine AI Platform - TipRanks

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace

Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus

Lantern Pharma establishes Open-Medicine AI to commercialize multi-agent AI co-scientist platform - TradingView

Lantern Pharma spins out AI platform into Open-Medicine AI - Investing.com

Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.com - Investing.com Canada

Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com Nigeria

Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus

Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer - Yahoo Finance

LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey

Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey

Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

TradingKey - TradingKey

Lantern Pharma Inc. Revenue Breakdown – NASDAQ:LTRN - TradingView

LTRN|Lantern Pharma Inc|Price:2.750|Chg%:-0.120 - TradingKey

Lantern Pharma (LTRN) investor Thomas Satterfield discloses 7.6% stake and 975,000 shares - Stock Titan

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - BioSpace

Lantern Pharma Inc Stock (LTRN) Financials Data

Revenue

Net Income

Cash Flow

EPS

Lantern Pharma Inc Stock (LTRN) Insider Trading

Similar to LTRN